Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NA-931 for Weight Management in Obesity or Overweight
NCT06564753Phase 2Completed
- Sponsor
- Biomed Industries
- Start
- Jul 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NA-931 in obesity and Overweight (5 arms), sponsored by Biomed Industries. Primary endpoint: Percent (relative) change from baseline to Week 13 in body weight. Started Jul 2024; status: completed.
02
Drugs
NA-931
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06564753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564753.